Please login to the form below

Not currently logged in
Email:
Password:

adverse events

This page shows the latest adverse events news and features for those working in and with pharma, biotech and healthcare.

Gilead says switching studies back new HIV therapy Biktarvy

Gilead says switching studies back new HIV therapy Biktarvy

Gilead’s data showed patients on Biktarvy had fewer mild-to-moderate adverse event reports and also that no patient in the Biktarvy arm developed resistance to drugs in the regimen ... In addition, people taking Biktarvy experienced fewer drug-related

Latest news

More from news
Approximately 5 fully matching, plus 327 partially matching documents found.

Latest Intelligence

  • A new era of smart pharma A new era of smart pharma

    Remote monitoring has its place but sponsors must still be able to collect detailed information on clinical endpoints, serious adverse events (SAEs) and events of special interest. ... SAEs). It is in this area that pharmacovigilance, the science

  • The tipping point The tipping point

    When conditioned to expect a negative response, otherwise known as the ‘nocebo’effect, patients are more likely to report adverse events, putting a brake on biosimilar adoption.

  • Gene therapy Gene therapy

    Because of his death, 652 previously unreported, serious adverse events, including deaths, were reported to the US National Institute of Health. ... As many of these trials were performed on very sick patients, it is unclear how many of these events can

  • Avoiding data pitfalls in clinical research Avoiding data pitfalls in clinical research

    When these algorithms are layered on traditional clinical data, sponsors can quickly identify changes in adverse events or therapeutic response. ... This is a deceptively difficult task, but once patient IDs are matched within the clinical trial database,

  • AI’s potential in the pharma life cycle AI’s potential in the pharma life cycle

    As more and more companies identify opportunities to turn AI-enabled insights into timely and beneficial outcomes - whether by accelerating market entry, successfully mining social media for potential adverse events and

More from intelligence
Approximately 0 fully matching, plus 14 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Nobull Communications

Switched on Creative Communications. With an encyclopedic working knowledge of pharmaceutical industry rules and regulations, we create dynamic, intuitive and...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics